Buy Rating Affirmed for Immatics Amidst Promising Clinical Trials and Strategic Positioning in TCR Therapeutics
Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Immatics (IMTX – Research Report) on October 11 and set a price target ...
Buy Rating Affirmed for IMTX on Strong Clinical Data and Attractive Valuation Post-Equity Financing
Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on IMTX stock, giving a Buy rating on October 7. Graig ...
BioWorld3d
Lundbeck values Longboard at $2.6B, gains bexicaserin
Lundbeck A/S is to acquire Longboard Pharmaceuticals Inc. in an all-cash deal valuing the epilepsy specialist at $2.6 billion. The agreed price of $60 per share is a 54% premium to the closing price ...
Science Daily3d
HIV and AIDS News
Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...
Immatics: A Promising TCR Pipeline
Immatics, a biotech company working on promising cell-based immunotherapies for solid cancers, has a promising TCR-engineered ...
precisionmedicineonline5d
Immatics Prices $150M Stock Offering
The firm plans to use the proceeds to advance its pipeline of T-cell receptor therapies and support their manufacturing, production, and commercialization.
U.S. Private Sector Prints $70 Billion Deficit And This Points To Lower Equity Prices In October
September 2024's negative private sector balance of -$70 billion suggests a likely decline in risk asset markets into October ...
precisionmedicineonline5d
Immatics Moving PRAME-Directed Autologous TCR T-Cell Melanoma Therapy to Phase III
The firm is gearing up for a registration-directed trial based on a positive Phase Ib readout and after discussions with US ...
The Pharma Letter6d
Immunotherapy firm Immatics prices $150 million public offering
German cancer specialist Immatics has priced a $150 million public offering with Jefferies, BofA Securities, and Leerink as ...
manilatimes6d
EpimAb Biotherapeutics Announces Upcoming Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T ...
Immatics Announces Pricing of $150 Million Public Offering
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development ...
BioWorld6d
FDA gives early approval to Genentech’s first-line breast cancer treatment
PDUFA date, the U.S. FDA has approved Genentech Inc.’s first-line breast cancer treatment Itovebi (inavolisib). Itovebi is to be combined with Pfizer Inc.’s palbociclib (Ibrance) and fulvestrant for ...